CEACAM5 and colorectal carcinoma: Furthermore, Morse and colleagues evaluated the safety and immunogenicity of the oncolytic adenovirus Ad5 [E1-, E2b-]-CEA(6D) or ETBX-011, manufactured by Etubics Corporation, in patients with CRC (33).